Lumaegis was recently honoured as one of the 2024 RadLaunch Challenge Winners by the International Ultraviolet Association, recognising its contributions to solid-state lighting-based sterilisation technologies.
Lumaegis has also successfully closed a $200,000 pre-seed funding round, led by one of their global strategic partners. Lumaegis will use these funds to build the next set of production units and conduct FDA, UL/CE, and longevity testing.
At the heart of Lumaegis’s innovation is the RadBox, a sterilisation device designed as a fast, energy-efficient alternative to traditional sterilisers. The RadBox has received FDA De Novo classification, a designation reserved for innovative technologies with no existing, approved predicate device. This status highlights the RadBox’s significant advantages and its potential to improve patient outcomes, while saving the practitioners tens of thousands of dollars per year.
The company is set to begin FDA-required testing later this year. The RadBox utilises dual-modality approach — a combination of germicidal and thermal radiation emitted by Light Emitting Diodes to achieve sterility. With key patent already granted and additional applications nearing completion, Lumaegis is preparing for commercial launch upon FDA De Novo approval.
“We anticipate our first sales in 2026,” said Lumaegis’s CEO John S Morreale. “Production will begin that year, and we already have customers lined up. Many dental professionals who collaborated with us during the RadBox design phase will be among our first users, providing essential clinical feedback. Additionally, we’ve secured our first major customer — a global industry partner and investor in the disinfection and sterilisation space — representing over 2,000 units in initial sales.”
Lumaegis is poised to redefine sterilisation standards across dental and medical practices, offering a transformative solution that combines speed, efficiency, and safety, all the while reducing practitioners’ costs and improving their productivity.
